Q-omics provides the consensus-scored GTF2H2C profile across patient tissues and cancer cell-line models. GTF2H2C expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GTF2H2C is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, GTF2H2C RNA expression shows 20,411 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where GTF2H2C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GTF2H2C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GTF2H2C survival associations across molecular data types. GTF2H2C RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GTF2H2C RNA expression–survival associations across cancer types. High GTF2H2C expression shows unfavorable associations in CESC, LIHC, KICH and UVM, but favorable associations in KIRC and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GTF2H2C RNA expression.
This table summarizes GTF2H2C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for GTF2H2C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GTF2H2C shows lower tumor expression in THCA, KIRC and KICH and higher tumor expression in LIHC, STAD and BRCA. The THCA box plot shows higher GTF2H2C RNA expression in normal versus tumor tissue (log2 FC = −0.659, t-test p < 0.001).
This table shows molecular features associated with GTF2H2C in patient tissues and cancer cell lines. In patient samples, GTF2H2C shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, GTF2H2C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
